

Why Would Anyone, Including ACIP, Still be Considering “Boosters” at this Point? And It Looks Like New Vaccines Are New Vaccines. Why That’s Important.

By [Dr. James Lyons-Weiler](#)

Global Research, April 22, 2022

[Popular Rationalism](#) 21 April 2022

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on [Instagram](#), [Twitter](#) and [Facebook](#). Feel free to repost and share widely Global Research articles.

It all just seems a grotesque waste of taxpayers’ dollars. The good news, upgrades to mRNA vaccines might be considered “New Vaccines”, as I’ve proscribed earlier. We’ll see.

According to [CNN](#), CDC’s Advisory Committee on Immunization Practices (ACIP) continue to “mull over” what’s next for Covid-19 boosters, and indeed are even considering what the “upgrades” Covid-19 vaccines. There are indications that they know that “entirely different vaccine formulations could be needed”.

Currently, additional booster doses are recommended only for certain people with weakened immune systems and adults 50 and older.

CDC quoted **Dr. Sara Oliver**, one of CDC’s epidemic intelligence service officers with the Division of Viral Diseases, who provided a robust soundbite:

“Policy around future doses require continued evaluation of Covid-19 epidemiology and vaccine effectiveness, including the impact of both time and variants, and the ability of doses to improve this protection.”

The specifics CNN cited Oliver as seeing CDC needing to take into account include recent case counts, hospitalization rates, and vaccine effectiveness in the US, and also – shocking – including whether it’s waning over time. They also cited that she thought CDC should weigh “the impacts of circulating coronavirus variants”.

We know vaccine effectiveness is unacceptably low – and given Dr. Fantini’s results may actually be negative, indicating disease enhancement.

Oliver stated that the evolution of the virus will be an important consideration for considering “platforms” for future COVID-19 vaccinations.

It’s not hard to read between the lines here. Readers of **#PopularRationalism** already know that the mRNA vaccines have proven to be worse than a dismal failure. This is CDC putting the word out that a second round of vaccine development is expected, and is about the closest we’ll ever see to CDC admitting the vaccination program has flopped.

And it’s surprising to see ACIP being focused on future “effectiveness”. Clearly, if newly formulated vaccines are proposed, they will be a square one in terms of the regulatory stage of development, and we should be seeing data on *efficacy*, which is a measure of a vaccine’s ability to reduce transmission in a prospective randomized clinical trial, not *effectiveness*, which is measured using real-world data.

As the real-world data on COVID-19 vaccine *effectiveness* came in, it was quite bad, so the net was lowered from “preventing transmission” and “reducing new infections” to “producing an antibody response”.

So far, according to [USASpending.Gov](https://www.usaspending.gov), the US has now spent over 3.63 trillion dollars in its response to COVID-19. According to the US Center for Economic Studies, the US suffered record-smashing loss of -9.5% of its GDP in 2020, and over 30% shrinkage in economic growth.

Nevertheless, both Pfizer and Moderna are taking a stab at vaccines meant to be available against Omicron, but it is doubted whether the variant will be around long enough to even be targeted by the new vaccines. Pfizer is hoping for a vaccine that will remain effective for more than a year, while Moderna’s non-peer-reviewed preprint containing data from their internal study of the efficacy of their bivalent vaccine was cited by CDC with the careful caveat that the preprint had “not been peer-reviewed or published in a professional journal.”

In the heyday of the pandemic, Pfizer and Moderna could get away with sending FDA assurances that they would share data mentioned in press releases once the FDA gave EUA or full-out approval. Now that the fog of the pandemic has lifted, it seems that the standard practice of labeling press releases, [such as Moderna’s recent one on their bivalent vaccine](#) as “Forward Looking Statements” is in place, so I suspect Moderna, Pfizer and the SEC got my memos.

Due to evidence of lack of efficacy and need, FDA, Pfizer and Moderna have delayed further consideration of COVID-19 vaccines for young children until June, according to Politico ([SeekingAlpha](#), [Politico](#)).

Unfortunately, the companies are still communicating “success” as equivalent with “antibody response” when we all know (or at least my immunology students know that they really should be measuring and reporting memory B-cell responses and the degree of match between the antibodies produced by B-cells upon reinfection and whatever variant or variants have taken over after Omicron is a distant memory.

CDC also shared that Kaiser Permanente – which profits from vaccine sales – was in the driver’s seat of the CDC’s ACIP committee, with Dr. Matthew Daley, ACIP Vaccine Working Group Chairperson and senior investigator at the Kaiser Permanente Institute for Health

Research issuing “marching orders” to the rest of ACIP to be “be more proactive than reactive” on the future of Covid-19 vaccinations.

This article is just a reminder to those who need it that #ParentsAreWatching, and that #ScientistsAreWatching, too.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

Featured image is from Mercola

The original source of this article is [Popular Rationalism](#)
Copyright © [Dr. James Lyons-Weiler](#), [Popular Rationalism](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. James Lyons-Weiler](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca